We have recently reported clear cell histology as a strong risk factor for VTE before treatment in ovarian cancer (Satoh et al, 2007), and clear cell carcinoma shows significantly stronger expression of tissue factor, a major factor in the procoagulant activities of cancer cells, as compared with non-clear cell carcinoma (Uno et al, 2007). The gene discussed is F3; the disease is ovarian cancer.